Zollinger-Ellison syndrome epidemiology and demographics
|
Zollinger-Ellison syndrome Microchapters |
|
Differentiating Zollinger-Ellison syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Zollinger-Ellison syndrome epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Zollinger-Ellison syndrome epidemiology and demographics |
|
FDA on Zollinger-Ellison syndrome epidemiology and demographics |
|
CDC on Zollinger-Ellison syndrome epidemiology and demographics |
|
Zollinger-Ellison syndrome epidemiology and demographics in the news |
|
Blogs on Zollinger-Ellison syndrome epidemiology and demographics |
|
Risk calculators and risk factors for Zollinger-Ellison syndrome epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]
Overview
The incidence of gastrinoma is approximately 0.5-2/million population/year worldwide.[1]. About 25 to 30 percent of gastrinomas, which can cause Zollinger-Ellison syndrome, are caused by multiple endocrine neoplasia type 1 (MEN1).[2]
References
- ↑ Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P; et al. (2012). "ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes". Neuroendocrinology. 95 (2): 98–119. doi:10.1159/000335591. PMC 3701449. PMID 22261919.
- ↑ National Institute of Diabetes and Digestive and Kidney Diseases.http://www.niddk.nih.gov/health-information/health-topics/digestive-diseases/zollinger-ellison-syndrome/Pages/facts.aspx#causes